GCM
ANIX icon

Graham Capital Management’s Anixa Biosciences ANIX Stock Holding History

Graham Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,082
Closed -$81.4K – 1145
2025
Q4 		$81.4K Buy
+26,082
New +$107K ﹤0.01% 1154

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Graham Capital Management's ANIX Position: Q1 2026 in Review

Graham Capital Management sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 26,082 shares — an estimated $81.4K sold.

Graham Capital Management first reported a position in ANIX in Q4 2025 and held it in 1 quarter. The position peaked at $81.4K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Graham Capital Management reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 26,082 Anixa Biosciences shares in Q1 2026, an estimated $81.4K.
  • Graham Capital Management first reported a position in Anixa Biosciences in Q4 2025 and held it in 1 quarter.
  • Graham Capital Management's Anixa Biosciences position peaked at $81.4K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.